Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $8.20

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given an average recommendation of “Reduce” by the twelve ratings firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.20.

FULC has been the subject of several analyst reports. JPMorgan Chase & Co. cut Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Leerink Partners lowered Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective for the company. in a research note on Tuesday, June 2nd. Finally, Citigroup cut shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently modified their holdings of the company. Suvretta Capital Management LLC raised its stake in shares of Fulcrum Therapeutics by 21.9% during the fourth quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock valued at $74,206,000 after acquiring an additional 1,180,111 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Fulcrum Therapeutics by 8.9% in the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after purchasing an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after purchasing an additional 1,589,000 shares during the period. Braidwell LP increased its holdings in Fulcrum Therapeutics by 1,294.7% during the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after purchasing an additional 2,841,734 shares during the period. Finally, Siren L.L.C. raised its position in Fulcrum Therapeutics by 20.5% during the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 400,000 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Up 1.9%

Shares of NASDAQ:FULC opened at $3.77 on Thursday. The stock has a market cap of $251.20 million, a PE ratio of -3.28 and a beta of 2.93. The company’s fifty day moving average is $6.07 and its 200 day moving average is $8.50. Fulcrum Therapeutics has a 52 week low of $2.83 and a 52 week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. Sell-side analysts anticipate that Fulcrum Therapeutics will post -0.76 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.